Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Molecular Oncology Research (2023) Volume 7, Issue 5

Immune cell-mediated anti-tumor actions when c-myb-selective antisense oligonucleotides are embedded in anti-GD2 immunoliposomes.

Fabio Zancolli *

Department of Molecular Biology, Australian National University, Canberra, Australia

*Corresponding Author:
Fabio Zancolli
Department of Molecular Biology
Australian National University
Canberra, Australia
E-mail: zancolli@fabio.au

Received:26-Aug-2023, Manuscript No. AAMOR-23-112360; Editor assigned:29-Aug-2023, PreQC No. AAMOR-23-112360 (PQ); Reviewed:12-Sep-2023, QC No. AAMOR-23-112360; Revised:18-Sep-2023, Manuscript No. AAMOR-23-112360 (R); Published:25-Sep-2023, DOI:10.35841/ aamor-7.5.196

Citation: Zancolli F. Immune cell-mediated anti-tumor actions when c-myb-selective antisense oligonucleotides are embedded in anti-GD2 immunoliposomes. J Mol Oncol Res. 2023;7(5):196

Visit for more related articles at Journal of Molecular Oncology Research

Introduction

Within the category of neoplastic growths, an encapsulated tumor stands out as a distinctive and fascinating entity. Encapsulated tumors differ from their more malignant cousins in that they have a distinct architectural characteristic: a fibrous capsule surrounds them. They can't infiltrate nearby tissues like invasive or aggressive tumors can and are distinguished by their encapsulation. The term "encapsulated tumors" refers to a broad category of benign tumors, each of which has its own unique histological features, biological origins, and clinical implications [1].

Cancer is still a major worldwide health issue that necessitates novel treatment strategies. A promising new area in the fight against cancer is immunotherapy, which uses the body's immune system to combat cancer. Researchers have been investigating various methods to strengthen the immune system's anti-tumor responses in recent years, and the integration of cutting-edge technologies has resulted in significant improvements in immunotherapy [2].

The use of anti-GD2 immunoliposomes equipped with c-myb-selective antisense oligonucleotides is one such development. This complex strategy combines the robust regulatory effects of c-myb suppression with the specificity of immunoliposomes targeting GD2, a surface antigen frequently expressed on neuroblastoma and other cancers [3].

An appealing target for immunotherapeutic interventions is GD2, a glycolipid attached to the cell membrane that is overexpressed in a number of neuroectodermal malignancies, including neuroblastoma. GD2-targeting monoclonal antibodies have showed promise in clinical trials, although their effectiveness may be constrained by things like immunosuppression and tumor heterogeneity. Immunoliposomes can help in this situation [4].

Immunoliposomes that target GD2 and c-myb suppression have a synergistic effect on immune cell-mediated anti-tumor responses. These customized nanoparticles have two functions when they are administered to tumor cells that are GD2-positive. First, they prevent the cancer cells from proliferating and expanding by directly inducing apoptosis, or cell death. Second, the c-myb inhibition starts a chain reaction of immunological reactions. Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) identify the dying tumor cells as potential targets. The production of danger signals and tumor-associated antigens during apoptosis aids in this detection [5].

Conclusion

Although the idea of using anti-GD2 immunoliposomes loaded with c-myb-selective antisense oligonucleotides is tremendously exciting, there are still a number of obstacles to overcome. More research is needed in the areas of delivery system optimization, c-myb inhibition safety and specificity, and potential resistance mechanisms. A novel strategy in cancer immunotherapy is the incorporation of c-myb-selective antisense oligonucleotides within anti-GD2 immunoliposomes. This cutting-edge approach has the potential to change the way cancer is treated by combining the accuracy of targeted liposomal delivery with the regulatory power of gene suppression.

References

  1. Gomes-da-Silva LC, Fernández Y, Abasolo I, Et al. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform. Nano Medic. 2013;8(9):1397-413.

    2. Indexed at, Google Scholar, Cross Ref

  2. Jin SE, Jin HE, Hong SS. Targeted delivery system of nanobiomaterials in anticancer therapy: From cells to clinics. Bio Med Res Intr. 2014;2014.

    3. Indexed at, Google Scholar, Cross Ref

  3. Tu J, Shen Y, Pang H, Et al. Targeted delivery of small and macromolecular drugs. 2010:171-215.

    4. Google Scholar

  4. Ahmed M, Goldgur Y, Hu J, Et al. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. Public Lib of Sci. 2013;8(5):e63359.

    5. Indexed at, Google Scholar, Cross Ref

  5. Hess JL, Bittner CB, Zeisig DT, Et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood. 2006;108(1):297-304

    6. Indexed at, Google Scholar, Cross Ref

Get the App